Controlled release powder and process for its preparation

Claim 2

A controlled release taste masked powder containing discrete micro-particles for use in edible pharmaceutical and other controlled release compositions, said powder comprising particles containing an active ingredient in intimate admixture with at least one non-toxic insoluble, permeable, impermeable, or biodegradable controlled release polymer, or mixtures thereof, in an amount effective to provide a predetermined and controlled release of said active ingredient, each of said particles being in the form of a micromatrix with the active ingredient uniformly distributed throughout the matrix, but not entirely coated by the polymer, said particles having an average size of from 0.1 to 125 μm, being unlikely to be significantly degraded or ground by any chewing action, and having a predetermined release of said active ingredient.

Claim 3

A controlled release powder according to claim 1, wherein the particles have an average size of from 5 to 100 μm.

Claim 4

A controlled release powder according to claim 1 wherein the active ingredient is a drug, a nutrient, a flavoring agent or a sweetening agent.

Claim 5

A controlled release powder according to claim 1 wherein the active ingredient is a coloring agent, a fragrance, a herbicide or a pesticide.

Claim 6

A controlled release powder according to claim 1 wherein the polymer is selected from the group consisting of: alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, polymers of acrylic and methacrylic acids and esters thereof, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes and polyurethanes and co-polymers thereof.

Claim 7

A process for preparing a controlled release powder according to claim 1, which comprises the steps of: (a) forming a solution of the polymer or polymers in a solvent; (b) dissolving or dispersing the active ingredient in said polymer solution to form an uniform mixture; and (c) removing the solvent from the mixture to obtain micro-particles having an average size of from 0.1 to 125 μm.

Claim 8

A process according to claim 6 wherein the particles obtained have an average size of from 5 to 100 μm.

Claim 9

A process according to claim 6 wherein the solvent is selected from the group consisting of: water, alcohols, ketones, halogenated aliphatic compounds, halogenated aromatic hydrocarbon compounds, aromatic hydrocarbon compounds and cyclic ethers or a mixture thereof, and the solvent is removed in step (c) by spray drying, use of an external liquid phase, phase separation, interfacial polymer deposition or coacervation.

Claim 10

A pharmaceutical composition containing a pharmaceutically effective amount of a controlled release powder according to claim 1.

Claim 11

A pharmaceutical composition containing a pharmaceutically effective amount of a controlled release powder according to claim 1 and which is in the form of tablets, capsules, suppositories, implants or ocular inserts.

Claim 12

A pharmaceutical composition according to claim 9 which is in the form of chewable tablets or melt tablets.

Claim 13

A pharmaceutical composition containing a pharmaceutically effective amount of a controlled release powder according to claim 1 and which is in the form of a cream, an ointment or a formulation suitable for transdermal delivery.

Claim 14

A pharmaceutical composition containing a pharmaceutically effective amount of a controlled release powder according to claim 1 and which is in the form of a liquid for oral, local or parenteral administration.

Claim 15

A pharmaceutical composition according to claim 12, which is in the form of eye drops, nasal drops, ear drops, a suspension, a syrup, or an infusion or injectable solution.

Claim 16

A pharmaceutical composition according to claim 9 wherein the active ingredient is selected from the group consisting of ibuprofen, actaminophen, 5-amino-salicyclic acid, dextromethorphan, propranolol, theophylline, diltiazem, methyldopa, pseudoephedrine, cimetidine, cephalexin, cephaclor, cephradine, naproxen, piroxicam, diazepam, diclofenac, indomethacin, amoxycillin, pivampicillin, bacampicillin, dicloxacillin, erythromycin, erythromycin stearate, lincomycin, codergocrine mesylate, doxycycline, dipyridamole, frusemide, triamterene, sulindac, nifedipine, atenolol, lorazepam, glibenclamide, salbutamol, trimethoprim/sulphamethoxazole, spironolactone, carbinoxamine maleate, guaiphenesin, metoprolol tartrate and potassium chloride.

Claim 17

A pharmaceutical composition according to claim 9 for oral administration, wherein the active ingredient is theophylline.

Claim 18

A pharmaceutical composition according to claim 9 for oral administration, wherein the active ingredient is acetaminophen.

Claim 19

A pharmaceutical composition according to claim 9 for oral administration, wherein the active ingredient is potassium chloride.

Claim 20

An oral formulation for administration to human and non-human animal which is substantially free of the taste of the active ingredient comprising a controlled release powder according to claim 1.

Claim 21

An oral formulation according to claim 19 which is in the form of a liquid, chewable tablet, melt tablet, foam, gel or gum.

Claim 22

A chewable gum which contains as sweetening agent aspartame-containing micro-particles according to claim 1.

Claim 23

A non-aqueous suspension of a highly water-soluble or water-insoluble active ingredient, wherein the active ingredient is in the form of micro-particles of a controlled release powder according to claim 1.

Claim 24

A non-aqueous suspension according to claim 22 wherein the highly water-soluble active ingredient is selected from the group consisting of dextromethorphan, guaiphenesin and pseudoephedrine and salts thereof and potassium chloride.

Claim 25

A controlled release antibiotic formulation substantially free from the taste of said antibiotic for pharmaceutical or veterinary use which comprises a controlled release powder according to claim 1.

Claim 26

An antibiotic formulation according to claim 24 wherein the powder is in the form of a non-aqueous suspension.

Claim 27

An antibiotic formulation according to claim 24 which is in the form of a reconstitutable aqueous suspension.

Claim 28

A controlled release powder containing discrete micro-particles for use in edible, pharmaceutical and other controlled release compositions, said powder comprising particles containing an active ingredient in intimate admixture with at least one non-toxic polymer, wherein said polymer substantially but not entirely coats the active ingredient, each of said particles being in the form of a micromatrix with the active ingredient uniformly distributed throughout the matrix, said particles having an average size of from 0.1 to 125 μm, and a dissolution rate of active ingredient from said particles which is substantially proportional to the square root of time, said active ingredient selected from the group consisting of: metoclopramide bromide, propantheline bromide, aluminium trisilicate, aluminum hydroxide, cimetidine, phenylbutazone, indomethacin, naproxen, ibuprofen, flurbiprofen, diclofenac, dexamethasone, prednisone, glyceryl trinitrate, isosorbide dinitrate, pentaerythritol tetranitrate, soloctidilum, vincamine, naftidrofuryl oxalate, co-dergocrine mesylate, cyclandelate, papaverine, nictoninic acid, erythromycin stearate, cephalexin, nalidixic acid, tetracycline hydrochloride, ampicillin, flucloxacillin sodium, hexamine mandelate, hexamine hippurate, flurazepam, diazepan, temazepam, amitryptyline, doxepin, lithium carbonate, lithium sulfate, chlorpromazine, thioridazine, trifluperazine, fluphenazine, piperothiazine, haloperidol, maprotiline hydrochloride, imipramine, desmethylimipramine, methylphenidate, ephedrine, epinephrine, isoproterenol, amphetamine sulfate, amphetamine hydrochloride, diphenhydramine, diphenylpyraline, chlorpheniramine, brompheniramine, bisacodyl, magnesium hydroxide, dioctyl sodium sulfosuccinate, ascorbic acid, alpha tocopherol, thiamine, pyridoxine, dicyclomine, diphenoxylate, verapamil, nifedipine, diltiazem, procainamide, disopyramide, bretylium tosylate, quinidine sulfate, quinidine gluconate, propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril, hydralazine, ergotamine, epsilon aminocaproic acid, protamine sulfate, acetylsalicylic acid, acetaminophen, codeine phosphate, codeine sulfate, oxycodone, dihydrocodeine tartrate, oxycodeinone, morphine, heroin, nalbuphine, butorphanol tartrate, pentazocine hydrochloride, cyclazacine, pethidine, buprenorphine, scopolamine, mefenamic acid, phenytoin sodium, sodium valproate, dantrolene sodium, tolbutamide, disbenase glucagon, insulin, triiodothyronine, thyroxine and propylthiouracil, furosemide, chlorthalidone, hydrochlorthiazide, spironolactone, triamterene, ritodrine, appetite fenfluramine hydrochloride, phentermine and diethylproprion hydrochloride, aminophylline, theophylline, salbutamol, orciprenaline sulphate, terbutaline sulphate, guaiphenesin, dextromethorphan, noscapine, carbocisteine, cetylpyridinium chloride, tyrothricin, chlorhexidine, phenylpropanolamine, pseudoephedrine, dichloralphenazone, nitrazepam, promethazine theoclate, ferrous sulfate, folic acid and calcium gluconate, sulphinpyrazone, allopurinol and probenecid.

Claim 29

A controlled release powder containing discrete micro-particles for use in edible, pharmaceutical and other controlled release compositions, said powder comprising particles containing an active ingredient in intimate admixture with at least one non-toxic polymer, wherein said polymer substantially but not entirely coats the active ingredient, each of said particles being in the form of a micromatrix with the active ingredient uniformly distributed throughout the matrix, said particles having an average size of from 0.1 to 125 μm, and a dissolution rate of active ingredient from said particles which is substantially proportional to the square root of time, said active ingredient selected from the group consisting of: metoclopramide bromide, propantheline bromide, aluminium trisilicate, aluminum hydroxide, cimetidine, phenylbutazone, indomethacin, naproxen, ibuprofen, flurbiprofen, diclofenac, dexamethasone, prednisone, glyceryl trinitrate, isosorbide dinitrate, pentaerythritol tetranitrate, soloctidilum, vincamine, naftidrofuryl oxalate, co-dergocrine mesylate, cyclandelate, papaverine, nictoninic acid, erythromycin stearate, cephalexin, nalidixic acid, tetracycline hydrochloride, ampicillin, flucloxacillin sodium, hexamine mandelate, hexamine hippurate, flurazepam, diazepan, temazepam, amitryptyline, doxepin, lithium carbonate, lithium sulfate, chlorpromazine, thioridazine, trifluperazine, fluphenazine, piperothiazine, haloperidol, maprotiline hydrochloride, imipramine, desmethylimipramine, methylphenidate, ephedrine, epinephrine, isoproterenol, amphetamine sulfate, amphetamine hydrochloride, diphenhydramine, diphenylpyraline, chlorpheniramine, brompheniramine, bisacodyl, magnesium hydroxide, dioctyl sodium sulfosuccinate, ascorbic acid, alpha tocopherol, thiamine, pyridoxine, dicyclomine, diphenoxylate, verapamil, nifedipine, diltiazem, procainamide, disopyramide, bretylium tosylate, quinidine sulfate, quinidine gluconate, propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril, hydralazine, ergotamine, epsilon aminocaproic acid, protamine sulfate, acetylsalicylic acid, acetaminophen, codeine phosphate, codeine sulfate, oxycodone, dihydrocodeine tartrate, oxycodeinone, morphine, heroin, nalbuphine, butorphanol tartrate, pentazocine hydrochloride, cyclazacine, pethidine, buprenorphine, scopolamine, mefenamic acid, phenytoin sodium, sodium valproate, dantrolene sodium, tolbutamide, disbenase glucagon, insulin, triiodothyronine, thyroxine and propylthiouracil, furosemide, chlorthalidone, hydrochlorthiazide, spironolactone, triamterene, ritodrine, appetite fenfluramine hydrochloride, phentermine and diethylproprion hydrochloride, aminophylline, theophylline, salbutamol, orciprenaline sulphate, terbutaline sulphate, guaiphenesin, dextromethorphan, noscapine, carbocisteine, cetylpyridinium chloride, tyrothricin, chlorhexidine, phenylpropanolamine, pseudoephedrine, dichloralphenazone, nitrazepam, promethazine theoclate, ferrous sulfate, folic acid and calcium gluconate, sulphinpyrazone, allopurinol and probenecid.

Claim 30

A controlled release powder according to claim 27, wherein the particles have an average size of from 5 to 100 μm.

Claim 31

A controlled release powder according to claim 27, wherein the active ingredient is a drug, a nutrient, a flavoring agent or a sweetening agent.

Claim 32

A controlled release powder according to claim 27, wherein the active ingredient is a coloring agent, a fragrance, a herbicide or a pesticide.

Claim 33

A controlled release powder according to claim 27, wherein the polymer is selected from the group consisting of: alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, polymers of acrylic and methacrylic acids and esters thereof, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes and polyurethanes and co-polymers thereof.

Claim 34

A process for preparing a controlled release powder according to claim 27, which comprises the steps of: (a) forming a solution of the polymer or polymers in a solvent; (b) dissolving or dispersing the active ingredient in said polymer solution to form a uniform mixture; and, (c) removing the solvent from the mixture to obtain micro-particles having an average size of from 1.0 to 125 μm.

Claim 35

A process according to claim 32 wherein the particles obtained have an average size of from 5 to 100 μm.

Claim 36

A process according to claim 32 wherein the solvent is selected from the group consisting of: water, alcohols, ketones, halogenated aliphatic compounds, halogenated aromatic hydrocarbon compounds, aromatic hydrocarbon compounds and cyclic ethers or a mixture thereof, and the solvent is removed in step (c) by spray drying, use of an external liquid phase, phase separation, interfacial polymer deposition or coacervation.

Claim 37

A pharmaceutical composition containing a pharmaceutically effective amount of a controlled release powder according to claim 27.

Claim 38

A pharmaceutical composition containing a pharmaceutically effective amount of a control release powder according to claim 27 and which is in the form of tablets, capsules, suppositories, implants or ocular inserts.

Claim 39

A pharmaceutical composition according to claim 35 which is in the form of chewable tablets or melt tablets.

Claim 40

A pharmaceutical composition containing a pharmaceutically effective amount of a controlled release powder according to claim 27 and which is in the form of a cream, an ointment or a formulation suitable for transdermal delivery.

Claim 41

A pharmaceutical composition containing a pharmaceutically effective amount of a controlled release powder according to claim 27 and which is in the form of a liquid for oral, local or parenteral administration.

Claim 42

A pharmaceutical composition according to claim 38, which is in the form of eye drops, nasal drops, ear drops, a suspension, a syrup, or an infusion or injectable solution.

Claim 43

A pharmaceutical composition according to claim 35 wherein the active ingredient is selected from the group consisting of ibuprofen, acetaminophen, 5-amino-salicylic acid, dextromethorphan, propranolol, theophylline, diltiazem, methyldopa, pseudoephedrine, cimetidine, cephalexin, cephaclor, cephradine, naproxen, piroxicam, diazepam, diclofenac, indomethacin, amoxycillin, pivampicillin, bacampicillin, dicloxacillin, erythromycin, erythromycin stearate, lincomycin, codergocrine mesylate, doxycycline, dipyridamole, frusemide, triamterene, sulindac, nifedipine, atenolol, lorazepam, glibenclamide, salbutamol, trimethoprim/sulphamethoxazole, spironolactone, carbinoxamine maleate, guaiphenesin, metoprolol tartrate and potassium chloride.

Claim 44

A pharmaceutical composition according to claim 35 for oral administration, wherein the active ingredient is theophylline.

Claim 45

A pharmaceutical composition according to claim 35 for oral administration, wherein the active ingredient is acetaminophen.

Claim 46

A pharmaceutical composition according to claim 35 for oral administration, wherein the active ingredient is potassium chloride.

Claim 47

An oral formulation for administration to human and non-human animals which is substantially free of the taste of the active ingredient comprising a controlled release powder according to claim 27.

Claim 48

An oral formulation according to claim 45 which is in the form of a liquid, chewable tablet, melt tablet, foam, gel or gum.

Claim 49

A chewable gum which contains as sweetening agent aspartame-containing micro-particles according to claim 27.

Claim 50

A non-aqueous suspension of a highly water-soluble or water-insoluble active ingredient, wherein the active ingredient is in the form of micro-particles of a controlled release powder according to claim 27.

Claim 51

A non-aqueous suspension according to claim 48 wherein the highly water-soluble active ingredient is selected from the group consisting of dextromethorphan, guaiphensin and pseudoephedrine and salts thereof and potassium chloride.

Claim 52

A controlled release antibiotic formulation substantially free from the taste of said antibiotic for pharmaceutical or veterinary use which comprises a controlled release powder according to claim 27.

Claim 53

An antibiotic formulation according to claim 50 wherein the powder is in the form of a non-aqueous suspension.

Claim 54

An antibiotic formation according to claim 50 which is in the form of a reconstitutable aqueous suspension.